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SUMMARY
Sox9 is a transcription factor expressed in most solid
tumors. However, the molecular mechanisms under-
lying Sox9 function during tumorigenesis remain un-
clear. Here, using a genetic mouse model of basal
cell carcinoma (BCC), the most frequent cancer in
humans, we show that Sox9 is expressed from the
earliest step of tumor formation in a Wnt/b-catenin-
dependent manner. Deletion of Sox9 together with
the constitutive activation of Hedgehog signaling
completely prevents BCC formation and leads to a
progressive loss of oncogene-expressing cells.
Transcriptional profiling of oncogene-expressing
cells with Sox9 deletion, combined with in vivo
ChIP sequencing, uncovers a cancer-specific gene
network regulated by Sox9 that promotes stemness,
extracellular matrix deposition, and cytoskeleton
remodeling while repressing epidermal differentia-
tion. Our study identifies the molecular mecha-
nisms regulated by Sox9 that link tumor initiation
and invasion.
INTRODUCTION
During tumor initiation, normal cells targeted by oncogenic mu-
tations undergo a series of molecular changes that promote their
renewal, leading to their clonal expansion and the acquisition of
invasive properties. Although the mutations leading to tumor for-
mation are relatively well known (Stratton, 2011), the temporality
of the molecular changes from the first oncogenic mutations to
the development of invasive tumors remains poorly understood.
It remains unclear what is the relative importance of the cancer
cell of origin, the microenvironment, and the molecular changes
downstream of the oncogenic stimuli leading to the rewiring of
normal cells into fully tumorigenic cells.
Basal cell carcinoma (BCC) is the most common cancer in hu-
mans and affects several million new patients each year across
theworld (Epstein, 2008). BCC arises from constitutive activation
of the Hedgehog (HH) signaling pathway following an activating
mutation in Smoothened (Smo) receptor or loss of Patched1
(Ptch1) function (Epstein, 2008). Using mouse models of BCC
that allow the expression of oncogenic Smo mutation (SmoM2)
in different epidermal compartments, we and others have previ-
ously shown that long-lived epidermal stem cells (SCs) residing
in the interfollicular epidermis (IFE) are the cells of origin of
SmoM2-induced BCC during physiological conditions (Wong
and Reiter, 2011; Youssef et al., 2010). By transcriptional
profiling of SmoM2-expressing cells during BCC initiation, we
and others demonstrated that adult IFE SCs undergo a profound
reprogramming into a fate that resembles embryonic hair follicle
(HF) progenitors (EHFPs) before progressing into invasive tu-
mors and identified Wnt-/b-catenin signaling as the major driver
of this cellular reprogramming (Yang et al., 2008; Youssef et al.,
2012). However, the molecular mechanisms downstream of Wnt
signaling that control tumor formation remain unclear.
Sox9, a transcription factor (TF) that controls cell fate decision
during the development and homeostasis of a broad range of tis-
sues, including the HF SCs (HFSCs) (Kadaja et al., 2014; Nowak
et al., 2008; Vidal et al., 2005), is expressed in a wide range of
cancers, including BCCs (Vidal et al., 2008). Sox9 deletion pre-
vents tumorigenesis in prostate and pancreatic mouse cancer
models (Kopp et al., 2012; Thomsen et al., 2010), and gain and
loss of Sox9 function in human cancer cell lines suggest that
Sox9 inhibits apoptosis and promotes proliferation, invasion,
and metastasis (Cai et al., 2013; Camaj et al., 2014; Wang
et al., 2008). However, the molecular mechanisms downstream
of Sox9 functions in cancer remain unknown.
Here, using conditional deletion of Sox9 in mouse models of
BCC, we investigated the role and the mechanisms underlying
Sox9 function during tumor formation. We found that Sox9 is
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Figure 1. Sox9 Is Required for BCC Initiation and Long-Term Maintenance of Oncogene-Expressing Cells
(A) IF of Sox9 in adult tail skin. SG, sebaceous gland.
(B) IF of Sox9 and SmoM2 in tail epidermis of K14CreER:SmoM2 mice 1, 4, 6, and 9 weeks after TAM administration. Dashed lines represent the BL.
(legend continued on next page)
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required downstream of Wnt/b-catenin signaling for the long-
term self-renewal of oncogene-expressing cells and tumor
formation. Transcriptional profiling combined with chromatin
immunoprecipitation (ChIP) sequencing (ChIP-seq) identified
a gene-regulatory network (GRN) directly regulated by Sox9
that controls self-renewing division, differentiation, adhe-
sion, extracellular matrix (ECM), and cytoskeleton remodeling
required for the progression of oncogene-targeted cells into
invasive tumors.
RESULTS
Sox9 Is Required for the Long-Term Maintenance of
Oncogene-Expressing Cells and BCC Formation
To define the role of Sox9 during tumorigenesis, we first as-
sessed its temporal appearance following oncogenic HH activa-
tion in adult epidermal cells. During adult homeostasis, Sox9 is
expressed exclusively by HFSCs and their progeny but not by
IFE keratinocytes (Figure 1A) (Nowak et al., 2008; Vidal et al.,
2005). However, after SmoM2 expression, Sox9 became
detectable in the IFE when SmoM2-targeted cells stopped
differentiating normally and adopted a placode-like morphology
(Figure 1B) and persisted in fully developed BCCs (Figure 1B).
Sox9 was also highly expressed in dysplasia and BCC arising
from Ptch1 deletion (Figure 1C), demonstrating that Sox9
expression is a common feature observed during BCC develop-
ment irrespective of the oncogenic hit. Wnt/b-catenin signaling
controls the reprogramming of adult IFE into EHFP-like fate
and is required for BCC initiation (Yang et al., 2008; Youssef
et al., 2012). To assess whether Wnt/b-catenin signaling is
required for the ectopic expression of Sox9 following oncogenic
HH signaling, we examined Sox9 expression following concom-
itant SmoM2 expression and b-catenin deletion. Interestingly,
b-catenin deletion completely prevented Sox9 expression
following SmoM2 expression 4 weeks following tamoxifen
(TAM) administration, a time point at which all SmoM2-express-
ing dysplasia expressed Sox9 (Figure 1D), suggesting that Wnt/
b-catenin signaling is required to initiate Sox9. To substantiate
this finding, we assessed whether administration of LGK974, a
Wnt signaling inhibitor (Liu et al., 2013), prevents Sox9 expres-
sion in SmoM2-induced cells. Oral administration of LGK974
for 14 days, starting 2 weeks after TAM administration,
completely prevented Sox9 (Figure 1E), further demonstrating
that Wnt signaling is necessary for the initial expression of
Sox9 following SmoM2 expression in adult IFE cells. We next as-
sessed whether Wnt signaling is also critical for the maintenance
of Sox9 expression. To that end, we induced SmoM2 expression
and started treating mice with LGK974 4 weeks after SmoM2 in-
duction, when dysplasia already expressed Sox9 (Figures 1B
and S1F). After 2 weeks of LGK974 administration, Sox9 was
no longer expressed in SmoM2-expressing cells (Figure 1E),
showing that Wnt signaling is required downstream of SmoM2
to initiate and sustain Sox9 expression. Altogether, these data
show that oncogenic HH activation in adult IFE leads to Sox9
expression through a Wnt/b-catenin-dependent mechanism.
To determine the role of Sox9 during BCC formation, we
performed conditional deletion of Sox9 together with SmoM2
expression and assessed the impact of Sox9 deletion on BCC
formation (Figures S1A and S1B). Administration of 25 mg TAM
over 10 days to K14CreER/Rosa26-SmoM2-YFP/Sox9flox/
flox (K14CreER:SmoM2:Sox9cKO) induced SmoM2 expres-
sion together with Sox9 deletion in most IFE cells (>95%)
(Figures 1G and S1C). Nine weeks following TAM adminis-
tration, K14CreER:Rosa26-SmoM2-YFP (K14CreER:SmoM2)
mice developed macroscopic hypervascularized lesions in the
tail and the ears, while K14CreER:SmoM2:Sox9cKO mice were
almost indistinguishable from the wild-type (WT) mice (Figures
S1D and S1E). Microscopic examination of the tail epidermis
4 weeks after TAM administration revealed that K14CreER:
SmoM2 mice present numerous dysplastic lesions that further
progress into BCC 9 weeks after TAM administration (Figure 1F),
as previously described (Youssef et al., 2012; Youssef et al.,
2010). In sharp contrast, in the absence of Sox9, while SmoM2
was detected in the epidermis of the K14CreER:SmoM2:
Sox9cKO, the IFE was hyperplastic or dysplastic but did not pre-
sent any sign of progression into invasive BCCs (Figure 1F). Sur-
prisingly, 16 weeks after TAM administration, the number of cells
expressing SmoM2 dramatically decreased, with a concomitant
increase in WT cells (Figures 1F, 1G, and S1G). While covering
about 95% of the IFE area 9 weeks after TAM administration,
SmoM2+ Sox9cKO cells represented less than 3% of the total
IFE cells after 32 weeks (Figures 1F and 1G). These data demon-
strate that Sox9 is required for the long-term maintenance of
oncogene-expressing cells.
Because it has been shown that BCC arising from Ptch1 loss
of function and Gli2 overexpression arise from the HFSCs and
their progeny (Grachtchouk et al., 2011; Kasper et al., 2011;
Wang et al., 2011), we next determined whether Sox9 is required
for BCC formation following Ptch1 deletion, the most frequent
mutation in BCC (Epstein, 2008). While the K14CreER:Ptch1
flox/flox (K14CreER:Ptch1cKO) developed numerous BCCs in
the ventral skin epidermis 6 weeks following TAM administration,
Sox9 deletion prevented Ptch1-induced BCC (Figures 1H and
1I), demonstrating that Sox9 is required for BCC formation
regardless of the oncogenic stimuli, the cell of origin, and the
body location from where the tumors arise.
(C) IF of Sox9 and K15 in ventral skin in K14CreER:Ptch1cKO mice, showing Sox9 expression at 3 and 9 weeks after TAM administration.
(D) IF of Sox9 in K14CreER:SmoM2:b-catenincKO mice.
(E) IF of Sox9 and SmoM2 in K14CreER:SmoM2 mice treated during 2 weeks with LGK974 or vehicle, starting either 2 or 4 weeks after TAM administration.
(F) IF of SmoM2 and b4 in K14CreER:SmoM2 and K14CreER:SmoM2:Sox9cKO at 4, 9, and 16 weeks after TAM administration.
(G) Quantification of chimerism of SmoM2+ cells deleted for Sox9 cells, WT cells, and SmoM2-expressing cells that escaped Sox9 deletion at 9, 16, 24, and
32 weeks after TAM administration to K14CreER:Rosa-SmoM2:Sox9cKO mice (9 weeks, n = 3; 16 weeks, n = 6; 24 weeks, n = 4; 32 weeks, n = 3 mice).
(H) Quantification of the tumor burden in K14CreER:Ptch1cKO and K14CreER:Ptch1cKO:Sox9cKO mice (n = 3 mice in each group) 6 weeks following TAM
administration.
(I) IF of Sox9 and the basal marker K14 in ventral skin of K14CreER:Ptch1cKO and K14CreERPtch1Sox9cKO mice.
Data represent the mean and SEM of at least three biological replicates. *p% 0.05; **p% 0.01; ***p% 0.001. The scale bars represent 50 mm.
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Figure 2. Sox9 Promotes Symmetric Renewal of Oncogene-Expressing Cells
(A) IF of activated caspase-3 and SmoM2 in K14CreER:SmoM2 and K14CreER:SmoM2:Sox9cKO mice 9 weeks after TAM administration.
(B) Quantification of the number of apoptotic cells (Casp3+SmoM2+/SmoM2+) in K14CreER:SmoM2 and K14CreER:SmoM2:Sox9cKOmice 4, 9, and 16 weeks
after TAM administration (nR 4,058 cells counted per time point).
(legend continued on next page)
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Sox9 Promotes Self-Renewing Division in
SmoM2-Expressing Cells
To determine the cellular mechanisms leading to the disappear-
ance of SmoM2-expressing cells in the absence of Sox9, we
first assessed whether Sox9 deletion increased apoptosis in
SmoM2-expressing cells (Figures 2A and S2A). No increase in
the number of active caspase-3-positive cells was observed at
any time point following SmoM2 expression and Sox9 deletion
(Figure 2B), showing that Sox9 does not inhibit apoptosis in
oncogene-expressing cells.
We next investigated whether the loss of Sox9 induces a
decrease in proliferation of oncogene-expressing cells, leading
to their outcompetition by WT cells. Examination of Ki67 immu-
nostaining revealed that Sox9 deletion did not lead to a decrease
in the proliferation of SmoM2-expressing cells (Figures 2C and
S2B). On the contrary, proliferation of SmoM2-expressing cells
was increased in absence of Sox9 (Figure 2D), suggesting that
Sox9 could promote quiescence rather than proliferation in
oncogene-expressing cells.
Because the loss of SmoM2+ cells was not due to increased
apoptosis or decreased proliferation, we assessed the possibil-
ity that Sox9 regulates the balance between self-renewal and
differentiation during tumorigenesis. During homeostasis, IFE
progenitors divide asymmetrically at the population level, giving
rise on average to one basal K5+ cell and one differentiated
suprabasal K1+ cell (Clayton et al., 2007; Mascre´ et al., 2012).
However, upon SmoM2 expression, basal IFE progenitors
stop dividing asymmetrically and differentiating into suprabasal
IFE cells and instead accumulate into basal-like lesions that
progressively invade the dermis (Youssef et al., 2012; Youssef
et al., 2010). During epidermal development, the orientation of
the spindle poles perpendicular to basal lamina (BL) promotes
skin stratification (Lechler and Fuchs, 2005). We thus assessed
the orientation of the spindle poles following SmoM2 expression
and Sox9 deletion by measuring the angle between the two cen-
trosomes (NuMA) and BL. At 4 weeks following TAM, SmoM2-
expressing basal IFE basal cells divided most frequently
perpendicular to the BL irrespective of Sox9 expression (Figures
2E and 2F). In contrast, the transition from dysplasia or hyper-
plasia to BCC was accompanied by an increase in parallel
division, which was further enhanced in fully invasive BCC
(Figure 2F). Interestingly, this switch from perpendicular to par-
allel cell division was prevented by Sox9 deletion (Figure 2F).
Although deletion of Sox9 did not affect the apicolateral polarity
of Par3 (Figure S2D), the segregation of Par3 in dividing (PH3+)
cells further supports the increase of symmetric cell division that
accompanied the progression from dysplasia to BCC (Figures
S2E and S2F).
To assess more directly whether Sox9 regulates the fate of
oncogene-expressing cells, we performed short-term lineage
tracing using 5-ethynyl-20-deoxyuridine (EdU) pulse-chase ex-
periments at 4 and 9 weeks following TAM administration. To
that end, we administrated EdU and analyzed the cells that
initially incorporated EdU and the fate and localization of their
progeny 24 hr after EdU administration (chase) (Figure S2C). Af-
ter 4 hr, all EdU+ cells were located along the BL (Figures 2G–2I).
At 4 weeks following TAM administration, many EdU+ cells were
found in suprabasal differentiated cells after 24 hr of chase (Fig-
ures 2G and 2I), consistent with the majority of asymmetric
cell division at this stage. In contrast, at 9 weeks following
TAM, in the presence of Sox9, the majority of SmoM2+ IFE cells
gave rise to two basal cells, whereas in the absence of Sox9,
many EdU+ cells were found in suprabasal differentiated cells,
as at 4 weeks (Figures 2G–2I), indicating that Sox9 inhibits asym-
metric cell fate outcome of oncogene-expressing cells during
tumor progression.
The decrease in symmetric division following Sox9 deletion
was accompanied by an increase production of differentiated
cells, as shown by the proportional increase of K1+ differentiated
cells in Sox9-deficient cells (Figures 2J and 2K). Altogether,
these data indicate that Sox9 controls the balance between sym-
metric and asymmetric cell division during skin tumorigenesis
and consequently the long-term maintenance of oncogene-
expressing cells.
Identification of Sox9 Direct Target Genes in BCC
To determine the molecular mechanisms by which Sox9 regu-
lates BCC formation, we assessed the molecular changes asso-
ciated with Sox9 deletion in SmoM2-expressing cells. To that
end, we purified SmoM2-expressing cells using fluorescence-
activated cell sorting (FACS) 9 weeks following TAM administra-
tion and performed microarray analysis of SmoM2-expressing
cells in the presence or in the absence of Sox9. Microarray
confirmed by RT-PCR analysis showed that all classical HH
target genes, such asGli1,Gli2, Ptch1, and Ptch2, were upregu-
lated by SmoM2 regardless of Sox9 expression (Figure 3A; Table
S1), showing that Sox9 does not regulate HH signaling during
BCC initiation. No difference in the expression of Wnt ligands,
Wnt receptors, or their target genes, such as Lef1 and Bgn,
were observed in SmoM2-expressing cells deficient for Sox9
(Figures 3A and S3A), showing that Sox9 does not control the
activation of Wnt/b-catenin signaling mediated by SmoM2
(C) IF of SmoM2 and Ki67 in K14CreER:SmoM2 and K14CreER:SmoM2:Sox9cKO mice 9 weeks after TAM administration.
(D) Quantification of the proliferative cells (Ki67+SmoM2+/SmoM2+) in K14CreER:SmoM2 and K14CreER:SmoM2:Sox9cKOmice 4, 9, and 16 weeks after TAM
administration (nR 8,721 cells counted per time point from nR 4 different mice).
(E) IF showing the method used to measure the angle between the two centrosomes (NuMA) and the BL (b4 integrin).
(F) Quantification of the angle of cell division in K14CreER:SmoM2 and in K14CreER:SmoM2:Sox9cKO mice (nR 132 total cells counted per genotype in five
different mice).
(G) IF of EdU and LamV showing incorporation of EdU after a 4 hr pulse and a 24 h pulse-chase.
(H and I) Quantification of the basal and suprabasal EdU-positive cells after an EdU pulse (4 hr) and a pulse-chase (24 hr) (nR 4,055 cells counted per time point
from n = 3 different mice).
(J) IF for the differentiation marker K1 and SmoM2.
(K) Quantification of the percentage of differentiated cells (K1+SmoM2+/SmoM2+) in K14CreER:SmoM2 and in K14CreER:SmoM2:Sox9cKOmice 4 and 9weeks
after TAM administration (nR 3,971 cells counted per time point from nR 6 different mice).
Data represent the mean and SEM of at least three biological replicates. *p% 0.05; **p% 0.01; ***p% 0.001. The scale bars represent 50 mm.
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expression. Similarly, microarray analysis, RT-PCR and immu-
nostaining showed no difference in the upregulation of EHFP
genes such as Lhx2, Cux1, Pcadh, and Runx1 in SmoM2-
expressing cells deficient for Sox9 (Figures 3B and S3A–S3D).
Altogether these data show that Sox9 does not control HH and
Wnt/b-catenin activation or the initial reprogramming of adult
IFE cells into EHFP-like fate during BCC initiation.
Our microarray analysis showed that Sox9 deletion induced
the downregulation of 593 genes and the upregulation of 447
genes by more than 2-fold in two independent biological exper-
iments (Figures 3C and 3D; Table S1). Sox9 deletion in SmoM2-
expressing cells induced a decrease in the expression of genes
promoting stemness (e.g., Tcf3, Tcf4,Hmga2, Tbx1) (Chen et al.,
2012; Nguyen et al., 2009; Nishino et al., 2008), quiescence (e.g.,
Nfatc1, Lrig1, Bmp6) (Blanpain et al., 2004; Horsley et al., 2008;
Jensen and Watt, 2006), ECM (e.g., Col4a4, Col16a1, Lama3,
Lamc2), cell adhesion (e.g., Itga1, Itgb6, Emb, Mcam), cyto-
skeleton remodeling (e.g., Palld, Gsn, Acf7), and invasion (e.g.,
Mmp10,Mmp13, Foxc1), as well as an increase in the expression
of genes regulating proliferation (e.g., Ccnb1, Ccnd2, Cdca2)
and IFE differentiation (e.g., Lor, Fil, and genes belonging to
the epidermal differentiation complex [EDC]).
To determine which of these differentially regulated genes
represent direct target genes, we performed Sox9 ChIP-seq in
primary BCCs induced by SmoM2 expression (Figure 3E). We
first identified the regions that were significantly enriched in the
Sox9 ChIP compared with the input DNA using MACS peak-call-
ing software with the false discovery rate (FDR) set to 5% (see
A
ve
ra
ge
 p
ea
k
po
si
tio
n
TSS
-3000
-2000
-1000
1000
2000
3000
0.
5
1.
0
1.
5
2.
0
2.
5G
A
C
B
K14CreER 
SmoM2
K14CreER 
SmoM2
Sox9cKO 
EHFP
318
39 35
100
495251 372
28,3% 27,4%
Downregulated
Epidermal 
differentiation
Pou3f1, Flg, Foxn1, Hrnr, Lor,  Sprr2a1, Tgm3, Satb1, Rptn, Lce1a1, Lce1a2, Lce1b, Lce1c, Lce1d,
Lce1f, Lce1h, Krt2
Mitosis Haus2, Aurkb, Cdca2, Bub1, Kif11, Kif20b, Spc25, Ccnb1, Ccng2, Ccnd2, Cenpa, Cenpf, Fam33a 
Cell adhesion Cd36, Cd97, Egfl6, Alcam, Emb, Cdh11, Fermt2, Flot2, Itga1, Itgb6, Itgb8, Mcam, Ncam1, Nrxn1, Hspg2,
Spon2 
Extracellular matrix Fras1, Frem2, Chl1, Col4a3, Col4a4, Col5a2, Col8a1, Col16a1, Ecm1, Fbln2, Lama3, Lama4, Lamb3,
Lamc2, Fbn2, Spon2, Vit
Cytoskeleton/invasion Palld, Gsn, Acf7, Myo1b, Myo5b, Foxc1, Mmp10, Mmp13, Cap1, Cspg4, Ccdc88a, Gdnf, Hbegf, Nrg1
Stemness Tcf3, Tcf4, Hmga2, Tbx1
Quiescence
209
50,9% 
(p = 9,42e-7) 
8090281 217312
47,4% 
(p = 2,13e-5) 
Up in 
Sox9cKO
Down in
Sox9cKO
ChIP
Bmp6, Nfatc1, Lrig1
D
F
H
Genes donwregulated following Sox9 deletion
Genes upregulated following Sox9 deletion
E
0217 14
BCC HFSC
Negatively regulatedK
Bmper
Ccnb1
Ccnd2
Pou3f1
Satb1
Foxn1
Rora
Lce1a1
Lce1b
Lce1c
Lor
Dusp6
Ephna2
Fam129a
Slc2a1
Slit
Tnc
11270 66
BCC HFSC
Positively regulated
14,3%
I
Bmp6
Itga1
Col4a3
Col8a1
Ecm1
Fbln2
Gdnf
Hmga2
Tbx1
Tcf3
Acf7
Palld
Cspg4
Foxc1
Lhx2
Inhbb
S100a4
Sulf2
Wwp2
Nfatc1
Tcf4
Common targets Cancer specific targets
Sema3e
100kb
2
0
2
0
B
C
C
H
F
Nfatc1
50kb
2
0
2
0
B
C
C
H
F
CD97
2,5
0
2,5
0
10kb
B
C
C
H
F
Gdnf
10kb
2,5
0
2,5
0
B
C
C
H
F
J L
Msrb3
4,7
0
4,7
0Sox9 ChIP
Input
EHFP
246
50 35
92
791573 441
33,6% 30%
Upregulated
K14CreER 
SmoM2
K14CreER 
SmoM2
Sox9cKO 
96,1% 100%
R
el
at
iv
e 
m
R
N
A
 e
xp
re
ss
io
n
(F
ol
d 
ch
an
ge
 o
ve
r W
T)
Gl
i1
Gl
i2
Pt
ch
1
Pt
ch
2
W
nt7
b
Fz
d3 Bg
n
So
x5
Lh
x2
Ru
nx
1
0
2
4
6
8
10
20
40
60
80
**
**
**
**
Hedgehog Wnt EHFP
K14CreER SmoM2 9W K14CreER SmoM2 Sox9cKO 9W
K14CreER SmoM2 4W K14CreER SmoM2 Sox9cKO 4W
Figure 3. Sox9 Activates and Represses
Gene Expression during Tumorigenesis
(A) Relative mRNA expression of genes involved
in HH signaling, Wnt signaling, and the EHFP
signature in FACS-isolated cells from K14CreER:
SmoM2 and in K14CreER:SmoM2:Sox9cKO
9 weeks after TAM administration assessed by
qRT-PCR. Fold changes were calculated over WT
using the delta delta CTmethod after normalization
over TBP. Data represent the mean and SEM of at
least three biological replicates.
(B) Venn diagrams of the EHFP, adult IFE SmoM2+,
and SmoM2:Sox9cKO gene signatures. Signa-
tures are generated by taking the genes with fold
changes higher or lower than +2 and 2, respec-
tively, compared with WT IFE in two biologically
independent microarray analyses.
(C and D) Table showing a list of genes (C) down-
regulated or (D) upregulated by more than 2-fold
9 weeks after TAM administration. Genes in red are
putative direct Sox9 target genes as determined by
ChIP-seq.
(E) Example of peak associated with Msrb3 in
ChIP-seq (blue track) and input DNA (black track).
Red bar denotes MACS peak position; gene is
represented in light blue, and boxes represent
exons. Arrow represents transcription orientation.
(F) Sox9 canonical motif, enriched in 60.25% of the
peaks identified.
(G) Average profile of ChIP peaks relative to TSS.
(H) Venn diagram representing the merge between
genes downregulated following Sox9 depletion
(green), genes upregulated following Sox9 deletion
(blue) in microarray expression, and genes that are
associated with a least one peak in ChIP-seq (red).
(I) Venn diagrams representing the genes directly
upregulated by Sox9 in BCC (green) and HFSCs
(red) (Kadaja et al., 2014).
(J) Common Sox9 targets in HFSCs and BCC.
Red bar denotes MACS peak position; gene is
represented in light blue, and boxes represent
exons. Arrow represents transcription orientation.
(K) Venn diagrams representing the genes directly
downregulated by Sox9 in BCC (green) that
showed no overlap with HFSCs (Kadaja et al.,
2014).
(L) Tumor-specific Sox9 target genes. Red bar
denotes MACS peak position; gene is represented
in light blue, and boxes represent exons. Arrow
represents transcription orientation.
*p% 0.05; **p% 0.01; ***p% 0.001.
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Experimental Procedures for further details) and defined the
genes displaying at least one Sox9 peak within the gene and
the 50 kb region surrounding the coding sequence.
Motif analysis revealed that 60.25% of the ChIP peaks iden-
tified contained the canonical Sox9 motif ‘‘AACAAT’’ (Figure 3F)
(Lefebvre et al., 1997), and these peaks were preferentially
clustered around the transcription start site (TSS) (Figure 3G).
Interestingly, 47.4% of the downregulated genes and 50.9%
of genes upregulated following Sox9 depletion were directly
bound by Sox9 (Figure 3H), supporting the notion that Sox9
acts as both transcriptional activator and repressor during
tumorigenesis (Figures 3I–3L), contrasting with its mainly tran-
scriptional activator function in HFSCs (Kadaja et al., 2014).
Among the 77 genes downregulated upon Sox9 loss of function
and directly bound by Sox9 in adult HFSCs, 11 genes (14.3%)
were commonly directly positively regulated by Sox9 during
HF homeostasis and BCC (e.g., Nfatc1, Sema3e, Tcf7l2/Tcf4),
which represent only 3.9% of the 239 genes upregulated and
directly bound by Sox9 during tumorigenesis (Figures 3I and
3J). In contrast to HFSCs (Kadaja et al., 2014), Sox9 did not
regulate the expression of Activin, Fzd receptors, or Lhx2, a
key regulator of HF fate (Rhee et al., 2006) (Figures 3A and
S3B). In addition, none of the 14 genes that were upregulated
by Sox9 deletion and bound by Sox9 in adult HFSCs were
upregulated in HFSCs following Sox9 deletion (Figures 3K and
3L). Sox9 has been proposed to act as pioneered binding at su-
per-enhancers (SEs) in HFSCs (Adam et al., 2015). In HFSCs,
Sox9 binds to 46% of SEs (174 of 374), whereas only 24%
(89 of 374) of HFSC SEs were bound by Sox9 in BCCs, corre-
sponding to less than 0.5% of Sox9 peaks in BCC. Among
the genes presenting Sox9 peaks in HFSC SEs, 9% were de-
regulated by Sox9 deletion in HFSC (e.g., Lhx2), whereas only
2% of the genes containing these SEs were deregulated by
Sox9 deletion in BCCs (e.g., Nfatc1), suggesting that Sox9 pref-
erentially binds these SEs and that they are more functionally
important in HFSC than in BCC. These data demonstrate that
although some of the molecular mechanisms controlled by
Sox9 in HFSCs (Kadaja et al., 2014) are partially reused during
BCC formation, Sox9 presents a broader and different set of
direct target genes during tumorigenesis, possibly related to
its higher expression (Figure S3F) or to specific cooperating
factors (Figure S3G) and presents a unique repressive function
during tumorigenesis.
Sox9 Directly Regulates Genes Promoting SC Renewal
and Quiescence
Our microarray and ChIP-seq analyses, confirmed by ChIP-
qPCR and qRT-PCR experiments showed that Sox9 directly
promoted the expression of several well-known regulators of
stemness, including Hmga2 (Nishino et al., 2008), Tbx1 (Chen
et al., 2012), and Tcf3 and Tcf4 (Nguyen et al., 2009) (Figures
4A–4C). Immunostaining showed that Hmga2, Tbx1, Tcf3, and
Tcf4 were expressed as dysplasia progressed into BCCs but
were absent following Sox9 deletion (Figures 4D–4F and S4A).
In addition, the expression of these genes co-localized with
Sox9 in human BCCs, supporting the notion that Sox9 regulates
the expression of stemness genes in human cancer as well (Fig-
ures S4B–S4D). These data indicate that in BCC Sox9 directly
controls the expression of key genes promoting stemness.
Interestingly, Sox9 negatively regulated cell proliferation by
directly regulating the expression of Bmp-Nftac1 axis that pro-
motes HFSC quiescence (Blanpain and Fuchs, 2009; Blanpain
et al., 2004; Horsley et al., 2008) (Figures 4G–4J). Nfatc1 was
directly induced by Sox9 in both HFSC and BCC at some com-
mon regulatory regions (Figures 3J, 4H, and 4I). In contrast,
Bmp6, which promotes the quiescence of normal HFSC (Blan-
pain et al., 2004), was directly activated by Sox9 in BCC but
not in HFSCs (Figures 4G–4I). Bmper, a potent inhibitor of Bmp
signaling (Moser et al., 2003) was also directly bound by Sox9
in BCC and was strongly upregulated following Sox9 deletion
(Figures 4G–4I). The number of pSmad1/5/8 positive cells
was strongly reduced in SmoM2-expressing cells following
Sox9 deletion (Figure 4K), showing the essential role of Sox9 in
regulating the activation of the Bmp-Nfatc1 axis during skin
tumorigenesis.
Sox9 Directly Represses Genes Controlling Epidermal
Differentiation during BCC Initiation
Sox9 deletion in oncogene-expressing cells resulted in the upre-
gulation of many key regulators of IFE differentiation, such as
Satb1 (Fessing et al., 2011), Pou3f1(Faus et al., 1994), Rora,
and Foxn1 (Dai et al., 2013), as well as many genes belonging
Figure 4. Sox9 Activates the Expression of Stemness Genes during Tumorigenesis
(A) Sox9 peaks in the regulatory regions of Hmga2, Tcf3, and Tcf4. Red bar denotes MACS peak position; gene is represented in light blue, and boxes represent
exons. Arrow represents transcription orientation.
(B) PCR quantification of Sox9 ChIP in the regulatory regions of Hmga2, Tbx1, Tcf3, and Tcf4. Sox9 ChIP is normalized over control IgG. Sox9-binding primers
(blue) are designed within the peak, while negative region primers (white) are designed 2 kb upstream of the peak.
(C) qPCR analysis showing relative mRNA expression of Tbx1, Hmga2, Tcf3, and Tcf4 in FACS-isolated cells from K14CreER:SmoM2 and in K14CreER:
SmoM2:Sox9cKO 4 and 9 weeks after TAM administration. Fold changes were calculated over WT using the delta delta CTmethod after normalization over TBP.
Data represent the mean and SEM of at least 3 biological replicates.
(D–F) IF for SmoM2 and (D) Tbx1, (E) Tcf3, and (F) Tcf4, in K14CreER:SmoM2 and K14CreER:SmoM2:Sox9cKOmice 4, 6, and 9 weeks after TAM administration.
(G) Sox9 peaks for Bmp6 and Bmper. Red bar denotes MACS peak position; gene is represented in light blue, and boxes represent exons. Arrow represents
transcription orientation.
(H) Quantification of the enrichment following immunoprecipitation for Nfatc1, Bmper, and Bmp6. Enrichment is normalized over control IgG. Sox9-binding
primers (blue) are designed within the peak, while negative region primers (white) are designed 2 kb upstream of the peak.
(I) qPCR analysis of Nfatc1, Bmp6, and Bmper on FACS-isolated cells from K14CreER:SmoM2 mice and in K14CreER:SmoM2:Sox9cKO mice 4 and 9 weeks
after TAM administration. Data are normalized over WT.
(J) Immunohistochemistry (IHC) showing expression of Nfatc1 in K14CreER:SmoM2 but not in K14CreER:SmoM2:Sox9cKO mice 9 weeks after TAM
administration.
(K) IHC for phosho-Smad1/5/8 in WT, K14CreER:SmoM2, and K14CreER:SmoM2:Sox9cKO mice.
The scale bars represent 50 mm. Data represent the mean and SEM of at least three biological replicates. *p% 0.05; **p% 0.01; ***p% 0.001.
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to the EDC, a locus containing many genes that regulate
epidermal differentiation such late cornified envelope (Lce) pro-
teins (Candi et al., 2005) (Figure 3D). ChIP-seq experiments
confirmed by ChIP-qPCR analysis showed that Sox9 directly
repressed the expression of these genes (Figures 5A–5C), sug-
gesting that Sox9 inhibits IFE differentiation upon SmoM2
expression, by directly repressing the expression of key tran-
scriptional factors that promote epidermal differentiation and
many genes of the EDC.
Sox9 Directly Controls ECM Remodeling, Cell Adhesion,
and Actin Cytoskeleton during Initiation
Transcriptional analysis and ChIP experiments revealed that
Sox9 positively regulated the expression of many components
of the ECM and cell adhesion, including collagens (e.g.,
Col4a3, Col4a4), laminins (e.g., Lama3, Lamb3), integrins (e.g.,
Itga6, Itgb6, and Itgb8), and adhesion proteins (e.g., Alcam,
Mcam), many of which were directly bound by Sox9 (Figures
3C and 6A–6C). Immunofluorescence (IF) and FACS analysis
confirmed the upregulation of several key components of the
BL (e.g., Col4) and adhesion proteins (e.g., Itga6, Mcam), as
SmoM2-expressing cells progressed from dysplasia to invasive
BCC, while Sox9 deletion prevented these changes (Figures 6D–
6F, S5A, and S5B). To analyze more precisely how Sox9 regu-
lates cell adhesion and ECM deposition, we performed electron
microscopy (EM) analysis 9 weeks following SmoM2 expression
in the presence or in the absence of Sox9. ECMwas more fragile
following Sox9 deletion, resulting in a number of gaps between
the collagen fibers; the BL was thinner; and the cell-cell adhe-
sions were severely impaired, with multiple gaps between cells
(Figures 6G and S5C–S5E). Using second harmonic generation
(SHG), we analyzed the structure and orientation of type I and
II collagen fibrils and found that progression from dysplasia to
invasive BCC is accompanied by a reorganization of the ECM
with highly organized thick collagen fibers surrounding the
tumorigenic lesions (Figure 6D). In contrast, the collagen fibers
were disorganized upon Sox9 deletion, indicating the essential
role of Sox9 in mediating ECM remodeling during tumorigenesis
(Figure 6D).
The recruitment of inflammatory cells in the tumor stroma
plays a critical role during tumor invasion and progression.
Although our transcriptional profiling and ChIP-seq data did
not provide evidence that Sox9 directly controls inflammation
and immunity, we have assessed the presence of immune and
inflammatory cells (CD45: pan-hematopoietic marker; F4/80:
monocyte marker; GR1: granulocyte marker; and CD3: T cell
marker) following SmoM2 expression and Sox9 deletion. At
dysplasia stage (4weeks) andduringBCCprogression (6weeks),
no differences in the number of inflammatory cells underlying
SmoM2-expressing cells were observed in the presence or
absence of Sox9 (Figures S6A–S6E). However, an increase in
the number of inflammatory cells, in particular monocytes and
macrophages, was observed at the stromal interface of the lead-
ing edge of invasive BCC lesions (Figures S6A–S6E), whereas at
the same time point, many fewer immune and inflammatory cells
were observed in Sox9-deficient SmoM2-expressing cells, sug-
gesting that the recruitment of inflammatory cells is associated
with later stage of BCC progression and that Sox9may indirectly
regulate this process.
Importantly, we found that Sox9 regulated directly and indi-
rectly the expression of key regulators of actin cytoskeleton
dynamics, which are essential for cell migration and invasion
(Figures 3C and 6H–6K). F-actin transduces the mechanical
force between the contractile cytoskeleton and the ECM to allow
cell migration. Gelsolin (Gsn), an actin filament severing and
capping protein, which promotes actin polymerization (Witke
et al., 1995), was profoundly downregulated upon Sox9 deletion
in SmoM2-expressing cells (Figure 6J), although no peaks were
found within 50 kb surrounding Gsn start site in Sox9 ChIP-seq.
In contrast, Sox9 directly promoted the expression of Palladin
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Figure 5. Sox9 Directly Represses Differen-
tiation during Tumorigenesis
(A) Sox9 peaks associated with Foxn1, Rora,
Satb1, Pou3f1, and a part of the EDC. Red bar
denotes MACS peak position; gene is represented
in light blue, and boxes represent exons. Arrow
represents transcription orientation.
(B) PCR quantification of Sox9 ChIP in the regula-
tory regions of Foxn1, Satb1, Rora, Lce1d, Lce1c,
and Lce1a1 genes. Enrichment is normalized over
control IgG. PCR primers (blue) are designed within
the peak and 2 kb upstream of the peak for nega-
tive controls.
(C) RT-qPCR analysis of key regulators of IFE
differentiation (Satb1, Rora, Foxn1, Pou3f1) and
genes belonging to the EDC (Lce1d, Lce1a2, and
Lce1i) in FACS-isolated cells from K14CreER:
SmoM2 mice and in K14CreER:SmoM2:Sox9cKO
mice 4 and 9 weeks after TAM administration. Fold
changes were calculated over WT using the delta
delta CT method after normalization over TBP.
Data represent the mean and SEM of at least three
biological replicates. Data represent the mean and
SEM of at least three biological replicates. *p %
0.05; **p% 0.01; ***p% 0.001.
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(Palld) (Figures 6H–6J), which directly binds to F-actin, and
crosslink actin filaments into bundles and acts as a scaffold
that recruits actin-binding protein to promote cell motility (Goi-
coechea et al., 2008; Najm and El-Sibai, 2014). Finally, Sox9
also regulates the expression of Macf1/Acf7 (Figures 6H–6J), a
microtubule-actin crosslinking protein that connects the micro-
tubule and the actin cytoskeleton and promotes the migration
of HFSCs (Wu et al., 2011).
To determine the functional role of Sox9 and its target genes in
the regulation of actin polymerization and bundling during BCC
progression, we analyzed the levels of F-actin during SmoM2-
induced tumorigenesis. Tumor progression from dysplasia to
BCCwas accompanied by an increase in polymerized actin (Fig-
ure 6K). Similarly in human BCCs, F-actin was also increased in
BCC, compared with the adjacent normal skin epidermis (Fig-
ure S5F). However, in the absence of Sox9, while actin mRNA
was unchanged (Figure 6J), no increase in F-actin was observed
following SmoM2 expression (Figure 6K), demonstrating the key
role of Sox9 in regulating actin polymerization during tumor initi-
ation. Altogether, these data reveal that Sox9 directly regulates
ECM deposition, cell adhesion, and actin cytoskeleton reorgani-
zation that accompany the early steps of BCC invasion.
DISCUSSION
Although Sox9 is expressed in many human cancers, little
is known about the molecular mechanisms by which Sox9
regulates tumorigenesis. Here, we show that Sox9 is rapidly
upregulated during the early steps of BCC initiation in a Wnt/
b-catenin-dependent manner and is essential for the long-term
self-renewal of oncogene-expressing cells and their acquisition
of invasive properties. Transcriptional profiling combined with
ChIP-seq uncovers a GRN directly regulated by Sox9 that plays
an essential role in promoting self-renewing division and repres-
sing the normal differentiation program of oncogene targeted
cells, as well as regulating ECM and cytoskeleton remodeling
required for tumor invasion (Figure 7).
Similarly to what was found during pancreas and prostate can-
cer development (Kopp et al., 2012; Thomsen et al., 2010), Sox9
is expressed at the early steps of BCC initiation and is essential
for tumor formation. During pancreatic cancer development, it
has been proposed that Sox9 promotes the reprogramming of
acinar cells into ductal-like cells upon KRasG12D expression fol-
lowed by pancreas injuries (Kopp et al., 2012). In contrast, during
BCC formation, Sox9 is not required for the initial reprogramming
step of adult IFE cells into EHFPs but is critical for the long-term
maintenance of oncogene-expressing cells, reminiscent of its
role during HFSC homeostasis (Nowak et al., 2008; Vidal et al.,
2005) and for tumor invasion. Surprisingly, the progressive loss
of Sox9-deficient oncogene-expressing cells was not due to an
increase in apoptosis or a decrease in cell proliferation. On the
contrary, the proliferation was even further increased following
Sox9 deletion, most probably because of the loss of Sox9-medi-
ated relative quiescence mediated by the Bmp/Nfatc1 axis.
Although Sox9 overexpression in human keratinocytes or
mouse epidermis promotes cell growth and inhibits epidermal
differentiation (Adam et al., 2015; Shi et al., 2013), as it does
during BCC development, Sox9 overexpression alone does
not appear to promote tumor formation (Adam et al., 2015; Shi
et al., 2013), suggesting that other pathways beside Sox9 activa-
tion are required downstream of oncogenic HH/Wnt-signaling
axis to promote BCC development. Transcriptional profiling of
oncogene-expressing cells deficient for Sox9 combined with
ChIP-seq uncovered a GRN controlled by Sox9 during BCC for-
mation. Although some of the Sox9 target genes, such Tcf3 or
Nfatc1, are commonly regulated by Sox9 in BCC and HFSC ho-
meostasis, Sox9 regulates a unique GRN during skin tumorigen-
esis. The most striking difference in the molecular mechanisms
controlled by Sox9 in HFSCs and BCC, is the dual transcriptional
activator and repressor functions of Sox9 during tumorigenesis,
while Sox9 acts mainly as a transcriptional activator in HFSCs
(Kadaja et al., 2014). During BCC carcinogenesis, Sox9 directly
inhibits the expression of key transcriptional regulators of normal
IFE differentiation such as Satb1, a TF essential for epidermal
stratification and differentiation (Fessing et al., 2011), Pou3f1,
which represses the expression of the basal keratins K14
and K5 during IFE differentiation (Faus et al., 1994), as well as
Foxn1 and Rora that promote IFE differentiation (Dai et al.,
Figure 6. Sox9 Directly Controls ECM, Adhesion, and Cytoskeleton Remodeling during Tumorigenesis
(A) Sox9 ChIP-seq peaks associated with Emb, Lama3, and Lamb3. Red bar denotes MACS peak position; gene is represented in light blue, and boxes represent
exons. Arrow represents transcription orientation.
(B) PCR quantification of Sox9 ChIP in the regulatory regions of Lamb3, Lama3, Col4a3,Mcam, and Emb. Enrichment is normalized over control IgG. PCR primers
are designed within the peak and 2 kb upstream of the peak for negative controls.
(C) qRT-PCR analysis of cell adhesion and ECM and cell adhesion genes in FACS-isolated cells from K14CreER:SmoM2 mice and in K14CreER:SmoM2:
Sox9cKOmice 4 and 9 weeks after TAM administration. Fold changes were calculated over K14CreER:SmoM2mice 4 weeks after TAM using the delta delta CT
method after normalization over TBP. Data represent the mean and SEM of at least three biological replicates.
(D) SHG analyzed by multiphoton confocal microscopy in WT, K14CreER:SmoM2, and K14CreER:SmoM2:Sox9cKO mice 4, 6, and 9 weeks after TAM
administration.
(E and F) Immunostaining of (E) a6 integrin and (F) Mcam and SmoM2 in K14CreER:SmoM2mice and in K14CreER:SmoM2:Sox9cKOmice 4, 6, and 9weeks after
TAM administration.
(G) EM analysis of WT, K14CreER:SmoM2, and K14CreE:SmoM2:Sox9cKO mice 9 weeks after TAM administration. BC, basal keratinocytes; D, dermis.
(H) Sox9 peaks associated with Acf7 and Palld.
(I) PCR quantification of Sox9 ChIP in the regulatory regions of Palld and Acf7. Enrichment is normalized over control IgG.
(J) Relative mRNA expression of actin cytoskeleton regulators in FACS-isolated cells from K14CreER:SmoM2 mice and in K14CreER:SmoM2:Sox9cKO mice 4
and 9 weeks after TAM administration. Data are normalized over K14CreER:SmoM2mice 4 weeks after TAM administration and represent the mean and SEM of
at least three biological replicates.
(K) IF of filamentary actin (F-actin) stained with phalloidin in K14CreER:SmoM2 and K14CreER:SmoM2:Sox9cKO mice.
Exposure time is 50ms for all acquisition. The scale bars represent 50 mm, except in (G), where it represents 100 nm. Data represent the mean and SEM of at least
three biological replicates. *p% 0.05; **p% 0.01; ***p% 0.001.
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2013). Moreover, Sox9 also directly inhibits the expression
of genes encoding for structural proteins associated with
epidermal terminal differentiation. The difference of Sox9 target
genes in normal HFSC and BCC formation may be related to
the higher level of Sox9 expression in BCC or, to the different
epigenetic landscape and set of TFs such as Zfx, an essential
gene for BCC formation (Palmer et al., 2014) that could coop-
erate with Sox9 to regulate gene expression in tumor cells.
In addition, to regulate the balance between self-renewal and
differentiation in oncogene-expressing cells by directly promoting
the expression of genes regulating stemness and repressing the
expression of genes that mediate IFE differentiation, Sox9 can
also regulate the long-termmaintenance of oncogene-expressing
cells by promoting the relative quiescence of tumor initiating cells,
as the slow-growing nature is one of the hallmarks of BCC (Ep-
stein, 2008). Sox9 promotes the relative quiescence of HFSCs
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Figure 7. Mechanisms Regulated by Sox9
during Tumorigenesis
(A) Model summarizing the role of Sox9 in BCC
formation.
(B) Schematic representation of the GRN underly-
ing Sox9 functions in an oncogene-expressing
cells. Sox9-mediated gene activation is repre-
sented by arrows while Sox9-mediated repression
is represented by red bars. Cellular functions are
enclosed in colored boxes.
and BCC-initiating cells by common and
distinct mechanisms. In both situations,
Sox9 directly promotes the expression of
Nfatc1, a TF that regulates HFSC quies-
cence (Horsley et al., 2008). Bmp and
Tgf-b signaling are two key pathways
promoting quiescence in the epidermis
(Blanpain and Fuchs, 2009). Although in
HFSC, Sox9 promotes HFSC quiescence
by directly stimulating the expression of
activin leading to the activation of the Tgf-
b pathway (Kadaja et al., 2014), during
skin tumorigenesis, Sox9 regulates Bmp
signaling by directly promoting the expres-
sion of Bmp6 and repressing the expres-
sion of Bmp inhibitor.
We found that invasion of BCC-initi-
ating cells is associated with a profound
remodeling of the ECM, cell adhesion,
and actin cytoskeleton. Our molecular
analysis revealed that Sox9 is a key
regulator of the cellular and molecular
changes associated with BCC invasion.
Sox9 directly promotes the expression
of key components of the ECM and the
BL such as laminins, collagens, andmole-
cules that promote adhesion to the ECM,
such as integrins as well as cell-cell adhe-
sion proteins expressed at the leading
edge of invasive BCC. The decrease in
the level of expression of several integ-
rins, including a6 integrin, may also partially explain the pro-
gressive loss of oncogene-expressing cells deficient for Sox9.
Indeed, a6 integrin is one of the most common upregulated
genes across many different SCs (Fortunel et al., 2003) and in
the skin IFE, a high level of integrins is associated with increased
SC potential (Jones and Watt, 1993).
Sox9 regulates cytoskeleton dynamics that occurred during
BCC invasion by directly controlling the expression of Palld,
which promotes actin polymerization in tumor cells and Acf7, a
molecule that regulates and coordinates actin cytoskeleton
and microtubule dynamics and controls the migration of HFSCs
(Wu et al., 2011), a physiological process reminiscent of the
collective migration occurring during BCC invasion.
In conclusion, our study uncovers the cellular and molecular
mechanisms, as well as the GRN regulated by Sox9 during the
early steps of skin tumor initiation and demonstrates that Sox9
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controls the long-term self-renewal of oncogene-expressing
cells by promoting symmetric renewing division and inhibiting
differentiation. In addition, Sox9 also acts as key orchestrator
of the ECM remodeling, cell adhesion, and cytoskeleton dy-
namics required for tumor invasion (Figure 7). These results
have important implications for the development of novel strate-
gies to block formation and invasion in the most frequent cancer
in humans.
EXPERIMENTAL PROCEDURES
Mice
Similar numbers of males and females were used for each experiment.
Detailed information regarding mice strains and housing are reported in Sup-
plemental Experimental Procedures. Experiments involving mice presented in
this work were approved by Comite´ d’E´thique du Bien Eˆtre Animal (Universite´
Libre de Bruxelles) under protocol number 483N. Experiments involving hu-
man samples presented in this work were approve by the ethics committee
of Erasmus Hospital under protocol number P2012/332.
Immunostaining
Immunostaining was performed as described previously (Youssef et al., 2012).
Detailed procedures are reported in Supplemental Experimental Procedures.
Light and Epifluorescence Microscopy
Images were acquired using an Axio Imager M1 microscope and an
AxioCamMR3 or MrC5 (Carl Zeiss). For expression level comparison, all
images were acquired at equal exposure.
Confocal Microscopy
Cryosections 30 mm thick were fixed in 4% paraformaldehyde and incubated
overnight with 7AAD to label nuclei. Z-stacks of equal thickness were sub-
jected to maximum-intensity projection using Zen Black (Carl Zeiss).
Detailed descriptions of all other microscopic procedures, transmission EM,
and focused ion beam/scanning EM are available in Supplemental Experi-
mental Procedures.
FACS Isolation of Oncogene-Expressing Cells
Isolation of keratinocytes and RNA extraction were performed as previously
described (Youssef et al., 2012). Briefly, tail skin keratinocytes were isolated
and stained with anti-CD34 and anti-a6 integrin antibodies. SmoM2-YFP+/
a6+/CD34+ living cells, corresponding to IFE and infundibulum cells, were har-
vested directly into the lysis buffer before extraction was performed according
to the manufacturer’s instruction (RNeasy Mini Kit; Qiagen). Detailed proce-
dures are reported in Supplemental Experimental Procedures.
Real-Time RT-PCR Analysis
qRT-PCR was performed as described previously (Youssef et al., 2012).
Briefly, after RNA quantification using NanoDrop, the purified RNA was used
to generate cDNA strand using SuperScript II polymerase (Invitrogen) and
random hexamers (Roche). qPCRwas performed using FastStart SYBRGreen
Master (Roche) on a LightCycler 96 device (Roche). Fold changes were calcu-
lated using the delta delta CT method after normalization over TBP. The list of
primers used is reported in Table S5.
ChIP-seq
Ten million keratinocytes isolated from tail epidermis of K14CreER:SmoM2
mice 9 weeks after TAM administration were crosslinked for 10 min with 1%
formaldehyde on a rotating wheel. The reaction was quenched by adding
0.125 M glycine and washed twice in PBS. ChIP was performed using the
EZ-Magna ChIP kit (Millipore) according to the manufacturer’s instruction for
all steps except lysis, which was carried using SDS lysis buffer (Millipore).
The chromatin was sonicated into 300 to 500 bp fragments using a Bioruptor
(Diagenode) coupled to a cooling system to maintain temperature at about
4C. Antibodies used for ChIP were Sox9 (Ab5535; Millipore) and control
immunoglobulin G (IgG) (Ab46540; Abcam).
Five to ten nanograms of ChIPed DNA were subjected to library prepara-
tion using the TruSeq ChIP Sample Prep Kit (Illumina), with small variations
described in Supplemental Experimental Procedures and sequenced on a
HiScanSQ module (Illumina).
ChIP Analysis
Briefly, unique mapped reads were aligned on mouse genome (NCBI Build 37/
UCSC mm9), and peaks were discovered using MACS software (version 1.4)
using an FDR threshold of 5%and aminimal fold enrichment of 2. Detailed pro-
cedures are described in Supplemental Experimental Procedures.
Microarray Analysis
RNA from FACS-purified cells was labeled and hybridized on amouse genome
430 2.0 array (Affymetrix) by AROS Applied Biotechnology A/S. Biological du-
plicates were performed for both K14CreER:SmoM2 and K14CreER:SmoM2:
Sox9cKO mice 9 weeks after induction. We considered genes upregulated or
downregulated by more than 2-fold in two independent biological duplicates.
ACCESSION NUMBERS
The accession number for the microarray data reported in this paper is GEO:
GSE68613. The accession number for the ChIP-seq data reported in this paper
is GEO: GSE68755.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, and five tables and can be found with this article online at http://
dx.doi.org/10.1016/j.stem.2015.05.008.
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